An innovative, first-in-class, anti-Polyomavirus drug for use as a prophylactic and/or therapeutic.
A novel, broad-spectrum coronavirus treatment to prevent COVID-19 variants and future coronavirus threats.
BK virus is one of the two most common viral infections that affect transplant patients. Nearly all kidney and most solid organ and bone marrow transplant recipients are at risk of BKV reactivation.
BK reactivation in patients begin with shedding virus in the urine (viruria) before leading to active infection in the blood (viremia) which ultimately results in BK virus associated nephropathy (BKVAN) and nephritis leading to graft failure.
The current standard of care is limited to reduction of immunosuppression in the transplant patient which predisposes the patient to graft rejection and life-threatening disease.
(1) Kidney transplants worldwide by region 2019 | Statista (2) J Bras Nefrol. Jan-Mar 2018;40(1):59-65. doi: 10.1590/1678-4685-JBN-3776. Epub 2018 Apr 19
has the potential to suppress BK reactivation and
replication thereby promoting graft survival.
Structure-based drug design and exciting mechanism of action.
Attractive pharmacokinetic profile, twice daily oral dosing.
Our lead molecule is in progression to IND-enabling studies and clinical proof of concept:
We are developing a therapeutic that can offer both prophylactic and therapeutic options.